Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major primary sclerosing cholangitis markets are expected to exhibit a CAGR of 5.84% during 2024-2034.

The primary sclerosing cholangitis market has been comprehensively analyzed in IMARC's new report titled "Primary Sclerosing Cholangitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary sclerosing cholangitis (PSC) refers to a chronic liver disease characterized by inflammation, scarring, and narrowing of the bile ducts inside as well as outside the liver. Some of the common symptoms include fatigue, itching (pruritus), abdominal pain or discomfort, jaundice, dark urine, pale stools, unintended weight loss, etc. These indications can vary in severity and may be intermittent. Additionally, the ailment is often associated with inflammatory bowel disease, particularly ulcerative colitis, and individuals suffering from PSC may experience various related symptoms, such as diarrhea, rectal bleeding, abdominal cramping, etc. Diagnosing primary sclerosing cholangitis involves a combination of clinical evaluation, imaging studies, and laboratory procedures. The diagnostic process typically begins with a thorough medical history and physical examination, followed by blood tests to assess liver function and identify specific serological markers associated with PSC. Numerous imaging techniques, including magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography, are used to visualize the bile ducts and check for characteristic abnormalities like strictures or narrowing. Additionally, a liver biopsy may be performed in certain cases to confirm the diagnosis or rule out other liver conditions.

The increasing cases of immune system dysfunction in which the immune system mistakenly attacks the bile ducts, thereby leading to inflammation and scarring, are primarily driving the primary sclerosing cholangitis market. Besides this, the rising prevalence of several associated risk factors, such as alterations in the composition and function of the gut microbiota, chronic inflammation in the bile ducts, genetic predisposition, a history of chronic bacterial cholangitis, etc., is propelling the market growth. Additionally, the widespread adoption of antibiotics, including ciprofloxacin and trimethoprim, for managing bacterial infections and preventing recurrent episodes of cholangitis is acting as another significant growth-inducing factor. Apart from this, the escalating application of immune modulators, such as obeticholic acid (OCA) and fibrates, to modulate the immune response and reduce liver inflammation in patients is also bolstering the market growth. Furthermore, the ongoing advancements in endoscopic techniques, including the introduction of digital cholangioscopy and single-operator cholangioscopy, which enable the removal of bile duct stones, biopsy of suspicious lesions, and dilation of strictures with improved precision, are expected to drive the primary sclerosing cholangitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the primary sclerosing cholangitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary sclerosing cholangitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary sclerosing cholangitis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the primary sclerosing cholangitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the primary sclerosing cholangitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current primary sclerosing cholangitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the primary sclerosing cholangitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the primary sclerosing cholangitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the primary sclerosing cholangitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of primary sclerosing cholangitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with primary sclerosing cholangitis across the seven major markets?
What is the size of the primary sclerosing cholangitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of primary sclerosing cholangitis?
What will be the growth rate of patients across the seven major markets?

Primary Sclerosing Cholangitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for primary sclerosing cholangitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary sclerosing cholangitis market?
What are the key regulatory events related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by status related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by phase related to the primary sclerosing cholangitis market?
What is the structure of clinical trial landscape by route of administration related to the primary sclerosing cholangitis market?